Inhibitory effects of amantadine on the production of pro-inflammatory cytokines by stimulated in vitro human blood

Pharmacological Reports

Volumn 61, Issue 6, 2009, Pages 1105-1112

  Kubera, Marta ^a   Maes, Michael ^b   Budziszewska, Bogusława ^a   Basta Kaim, Agnieszka ^a   Leśkiewicz, Monika ^a   Grygier, Beata ^a   Rogóz, Zofia ^a   Lasoń, Władysław ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

^b Clinical Research Center for Mental Health of Antwerp   (Belgium)

Author keywords

Amantadine; Fluoxetine; Imipramine; Interleukin 10; Pro inflammatory cytokines

Indexed keywords

AMANTADINE; CYTOKINE; FLUOXETINE; GAMMA INTERFERON; IMIPRAMINE; INTERLEUKIN 10; SEROTONIN UPTAKE INHIBITOR; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CYTOKINE PRODUCTION; DEPRESSION; DRUG EFFECT; FEMALE; HUMAN; IMMUNOMODULATION; IN VITRO STUDY; MALE; SEX DIFFERENCE; TREATMENT OUTCOME;

EID: 76049130643     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(09)70173-2     Document Type: Article

References (48)

1. Alaniz RC, Thomas SA, Perez-Melgosa M, Mueller K, Farr AG, Palmiter RD, Wilson CB: Dopamine β-hydroxylase deficiency impairs cellular immunity. Proc Natl Acad Sci USA, 1999, 96, 2274-2278.
2. Arai A, Kannari K, Shen H, Maeda T, Suda T, Matsunaga M: Amantadine increases L-DOPA-derived extracellular dopamine in the striatum of 6-hydroxydopaminelesioned rats. Brain Res, 2003, 972, 229-234.
3. Basso AM, Gioino G, Molin VA, Cancela LM: Chronic amphetamine facilitates immunosuppression in response to a novel aversive stimulus: reversal by haloperidol pre-treatment. Pharmacol Biochem Behav, 1999, 62, 307-314.
4. Basu S, Dasgupta PS: Dopamine, a neurotransmitter, influences the immune system. J Neuroimmunol, 2000, 102, 113-124.
5. Bergquist J, Tarkowski A, Ekman R, Ewing A: Discovery of endogenous catecholamines in lymphocytes and evidence for catecholamine regulation of lymphocyte function via an autocrine loop. Proc Natl Acad Sci USA, 1994, 91, 12912-12916.
6. Besser MJ, Ganor Y, Levite M: Dopamine by itself activates either D2, D3 or D1/D5 dopaminergic receptors in normal human T-cells and triggers the selective secretion of either IL-10, TNFα or both. J Neuroimmunol, 2005, 169, 161-171.
7. Boldyrev AA, Kazey VI, Leinsso TA, Mashkina AP, Tyulina OV, Johnson P, Tuneva JO et al.: Rodent lymphocytes express functionally active glutamate receptors. Biochem Biophys Res Commun, 2004, 324, 133-139.
8. Boukhris W, Kouassi E, Descotes J, Cordier G, Revillard JP: Impaired T-dependent immune response in L-dopa treated BALB/c mice. J Clin Lab Immunol, 1987, 23, 185-189.
9. Centers for Disease Control and Prevention (CDC). Update: drug susceptibility of swine-origin influenza A (H1N1) viruses, April 2009. MMWR Morb Mortal Wkly Rep, 2009, 58, 433-435.
10. Clark C, Woodson MM, Nagasawa HT: Inhibition of lymphocyte proliferation by amantadine and its isomer, 2-aminoadamantane; impact on Lyt-2+ T cells while sparing L3T4+ T cells. Immunopharmacology, 1991, 21, 41-50.
11. Clark C, Woodson MM, Winge VB, Nagasawa HT: The antiviral drug amantadine has a direct inhibitory effect on T-lymphocytes. Immunopharmacology, 1989, 18, 195-204.
12. Cook-Mills JM, Cohen RL, Perlman RL, Chambers DA: Inhibition of lymphocyte activation by catecholamines: evidence for a non-classical mechanism of catecholamine action. Immunology, 1995, 85, 544-549.
13. De Groote D, Zangerle PF, Gevaert Y, Fassotte MF, Beguin Y, Noizat-Pirenne F, Pirenne J et al.: Direct stimula-tion of cytokines (IL-1β, TNF-α, IL-6, IL-2, IFN-γ and GM-CSF) in whole blood. I. Comparison with isolated PBMC stimulation. Cytokine, 1992, 4, 239-248.
14. Dietrich DE, Bode L, Spannhuth CW, Lau T, Huber TJ, Brodhun B, Ludwig H, Emrich HM: Amantadine in depressive patients with Borna disease virus (BDV) infection: an open trial. Bipolar Disord, 2000, 2, 65-70.
15. Di Loreto S, Balestrino M, Pellegrini P, Berghella AM, Del Beato T, Di Marco F, Adorno D: Blockade of Nmethyl-D-aspartate receptor prevents hypoxic neuronal death and cytokine release. Neuroimmunomodulation, 1997, 4, 195-199.
16. Ferszt R, Kühl KP, Bode L, Severus EW, Winzer B, Berghöfer A, Beelitz G et al.: Amantadine revisited: an open trial of amantadine sulfate treatment in chronically depressed patients with Borna disease virus infection. Pharmacopsychiatry, 1999, 32, 142-147.
17. 1 and proinflammatory cytokine production in nicotinic acetylcholine receptor α7 subunit gene knockout mice. J Neuroimmunol, 2007, 189, 69-74.
18. Ghosh MC, Mondal AC, Basu S, Banerjee S, Majumder J, Bhattacharya D, Dasgupta PS: Dopamine inhibits cytokine release and expression of tyrosine kinases, Lck and Fyn in activated T cells. Int Immunopharmacol, 2003, 3, 1019-1026.
19. Kavelaars A, Cobelens PM, Teunis MA, Heijnen CJ: Changes in innate and acquired immune responses in mice with targeted deletion of the dopamine transporter gene. J Neuroimmunol, 2005, 161, 162-168.
20. Kouassi E, Boukhris W, Descotes J, Zukervar P, Li YS, Revillard JP: Selective T cell defects induced by dopamine administration in mice. Immunopharmacol Immunotoxicol, 1987, 9, 477-487.
21. Kubera M., Basta-Kaim A, Budziszewska B, Rogóż Z, Skuza G, Lékiewicz M, Tetich M et al.: Effect of amantadine and imipramine on behavioral, immunological and endocrinological parameters of rats subjected to a forced swimming test. Int J Neuropsychopharmacol, 2006, 9, 297-305.
22. Kubera M, Basta-Kaim A, Wróbel A, Maes M, Dudek D: Increased mitogen-induced lymphocyte proliferation in treatment resistant depression: a preliminary study. Neuro Endocrinol Lett, 2004, 25, 207-210.
23. Kubera M, Filip M, Basta-Kaim A, Nowak E, Budziszewska B, Tetich M, Holan V et al.: The effect of amphetamine sensitization on mouse immunoreactivity. J Physiol Pharmacol, 2002, 53, 233-242.
24. Kubera M, Lin A-H, Kenis G, Bosmans E, van Bockstaele D, Maes M: Anti-inflammatory effects of antidepressants through suppression of the interferon-γ/interleukin-10 production ratio. J Clin Psychopharmacol, 2001, 21, 199-206.
25. Kubera M, Maes M: Serotonin-immune interactions in major depression. In: Neuro-immune interactions in neurologic and psychiatric disorders. Eds. Petterson et al., Springer-Verlag, Berlin Heidelberg, 2000, 79-87.
26. Kubera M, Skowron-Cendrzak A, Mazur-Kolecka B, Bubak-Satora M, Basta-Kaim A, Laskowska-Bożek H, Ryżewski J: Stress-induced changes in muscarinic and β-adrenergic binding sites on rat thymocytes and lymphocytes. J Neuroimmunology, 1992, 37, 229-236.
27. Maes M, Yirmyia R, Noraberg J, Brene S, Hibbein J, Perini G, Kubera M et al: The inflammatory & neurodegenerative (I&ND) hypothesis of depression: leads for future research and new drug developments in depression. Metab Brain Dis, 2009, 24, 27-53.
28. Maj J, Rogóż Z: Synergistic effect of amantadine and imipramine in the forced swimming test. Pol J Pharmacol, 2000, 52, 111-114.
29. Mastronardi CA, Yu WH, McCann S: Lipopolysaccharide-induced tumor necrosis factor-alpha release is controlled by the central nervous system. Neuroimmunomodulation, 2001, 9, 148-156.
30. Masuda Y, Kondoh M, Suzuki M, Ohnuma S, Shimizu T, Hishikawa T: Participation of dopamine and norepinephrine in the secretion of interleukin-2 and interleukin-6 from the spleen of mice in different immune responses. Med Sci Res, 1995, 23, 851-852.
31. Miglio G, Dianzani C, Fallarini S, Fantozzi R, Lombardi G: Stimulation of N-methyl-D-aspartate receptors modulates Jurkat T cell growth and adhesion to fibronectin. Biochem Biophys Res Commun, 2007, 361, 404-409.
32. Miglio G, Varsaldi F, Lombardi G: Human T lymphocytes express NMDA receptors functionally active in controlling T cell activation. Biochem Biophys Res Commun, 2005, 338, 1875-1883.
33. Miller AH, Maletic V, Raison CL: Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry, 2009, 65, 732-741.
34. Nagatsu T, Mogi M, Ichinose H, Togari A: Changes in cytokines and neurotrophins in Parkinson's disease. J Neural Transm, Suppl, 2000, 60, 277-290.
35. + T cell activation during the development of stress-induced herpes simplex virus type-1 encephalitis. Brain Behav Immun, 2007, 21, 791-806.
36. Rogóż Z, Dziedzicka-Wasylewska M, Daniel WA, Wójcikowski J, Dudek D, Wróbel A, Ziȩba A: Effects of joint administration of imipramine and amantadine in patients with drug-resistant unipolar depression. Pol J Pharmacol, 2004, 56, 735-742.
37. Rogóż Z, Kubera M, Rogóż K, Basta-Kaim A, Budziszewska B: Effect of co-administration of fluoxetine and amantadine on immunoendocrine parameters in rats subjected to a forced swimming test. Pharmacol Rep, 2009, 61, 1050-1060.
38. Rogóż Z, Skuza G, Legutko B: Repeated co-treatment with fluoxetine and amantadine induces brain-derived neurotrophic factor gene expression in rats. Pharmacol Rep, 2008, 60, 817-826.
39. Rogóż Z, Skuza G, Daniel WA, Wójcikowski J, Dudek D, Wróbel A: Amantadine as an additive treatment in patients suffering from drug-resistant unipolar depression. Pharmacol Rep, 2007, 59, 778-784.
40. Rogóż Z, Skuza G, Kuśmider M, Wójcikowski J, Kot M, Daniel WA: Synergistic effect of imipramine and amantadine in the forced swimming test in rats. Behavioral and pharmacokinetic studies. Pol J Pharmacol, 2004, 56, 179-185.
41. Rogóż Z, Skuza G, Maj J, Danysz W: Synergistic effect of uncompetitive NMDA receptor antagonists and anti-depressant drugs in the forced swimming test in rats. Neuropharmacology, 2002, 42, 1024-1030.
42. Służewska A: Indicators of immune activation in depressed patients. In: Cytokines: Stress and depression. Eds. Dantzer A, Yirmia R, Kluwer Academic/Plenum Publishers, New York,1999, 59-73.
43. Służewska A, Rybakowski J, Sobieska M, Bosmans E, Pollet H, Wiktorowicz K: Increased levels of alpha-1-acid glycoprotein and interleukin-6 in refractory depression. Depression, 1996, 39, 149-155.
44. Sookhai S, Wang JH, Winter D, Power C, Kirwan W, Redmond HP: Dopamine attenuates the chemoattractant effect of interleukin-8: a novel role in the systemic inflammatory response syndrome. Shock, 2000, 14, 295-299.
45. Takahashi HK, Iwagaki H, Hamano R, Kanke T, Liu K, Sadamori H, Yagi T et al: The immunosuppressive effects of nicotine during human mixed lymphocyte reaction. Eur J Pharmacol, 2007, 559, 69-74.
46. Torre F, Rossel S, Pelli N, Basso M, Delfino A, Picciotto A: Kinetics of soluble tumour necrosis factor (TNF)-α receptors and cytokines in the early phase of treatment for chronic hepatitis C: Comparison between interferon (IFN)-α alone, IFN-α plus amantadine or plus ribavirin. Clin Exp Immunol, 2004, 136, 507-512.
47. Torres KC, Antonelli LR, Souza AL, Teixeira MM, Dutra WO, Gollob KJ: Norepinephrine, dopamine and dexamethasone modulate discrete leukocyte subpopulations and cytokine profiles from human PBMC. J Neuroimmunol, 2005, 166, 144-157.
48. Tuneva EO, Bychkova ON, Boldyrev AA: Effect of NMDAon production of reactive oxygen species by human lymphocytes. Bull Exp Biol Med, 2003, 136, 159-161.